Ann Clin Transl Neurol

. 2025 Jul 14.

doi: 10.1002/acn3.70106. Online ahead of print.

The MSA Atrophy Index (MSA-AI): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy

Paula Trujillo ¹, Kilian Hett ¹, Amy Cooper ¹, Amy E Brown ¹, Jessica Iregui ¹, Manus J Donahue ¹, M Erik Landman ², Italo Biaggioni ³, Margaret Bradbury ⁴, Cynthia Wong ⁴, David Stamler ⁴, Daniel O Claassen ¹

Affiliations Expand

• PMID: 40660627

DOI: 10.1002/acn3.70106

Abstract

Objective: Reliable biomarkers are essential for tracking disease progression and advancing treatments for multiple system atrophy (MSA). In this study, we propose the MSA Atrophy Index (MSA-AI), a novel composite volumetric measure to distinguish MSA from related disorders and monitor disease progression.

Methods: Seventeen participants with an initial diagnosis of probable MSA were enrolled in the longitudinal bioMUSE study and underwent 3T MRI, biofluid analysis, and clinical assessments at baseline, 6, and 12 months. Final diagnoses were determined after 12 months using clinical progression, imaging, and fluid biomarkers. Ten participants retained an MSA diagnosis, while five were reclassified as either Parkinson disease (PD, n = 4) or dementia with Lewy bodies (DLB, n = 1). Cross-sectional comparisons included additional MSA cases (n = 26), healthy controls (n = 23), pure autonomic failure (n = 23), PD (n = 56), and DLB (n = 8). Lentiform nucleus, cerebellum, and brainstem volumes were extracted using deep learning-based segmentation. Z-scores were computed using a normative dataset (n = 469) and integrated into the MSA-AI. Group differences were tested with linear regression; longitudinal changes and clinical correlations were assessed using mixed-effects models and Spearman correlations.

Results: MSA patients exhibited significantly lower MSA-AI scores compared to all other diagnostic groups (p < 0.001). The MSA-AI effectively distinguished MSA from related synucleinopathies, correlated with baseline clinical severity (ρ = -0.57, p < 0.001), and predicted disease progression (ρ = -0.55, p = 0.03). Longitudinal reductions in MSA-AI were associated with worsening clinical scores over 12 months (ρ = -0.61, p = 0.01).

Interpretation: The MSA-AI is a promising imaging biomarker for diagnosis and monitoring disease progression in MSA. These findings require validation in larger, independent cohorts.




This is similar to what we have seen in his meeting posters.